摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Methyl-[1,3]oxazolo[5,4-d]pyrimidine

中文名称
——
中文别名
——
英文名称
2-Methyl-[1,3]oxazolo[5,4-d]pyrimidine
英文别名
——
2-Methyl-[1,3]oxazolo[5,4-d]pyrimidine化学式
CAS
——
化学式
C6H5N3O
mdl
——
分子量
135.12
InChiKey
BKJFQCADPGMGPO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    51.8
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
    申请人:BlinkBio, Inc.
    公开号:US20170202970A1
    公开(公告)日:2017-07-20
    Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.
    本文描述了基于的共轭物,能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个-杂原子核心,一个或多个可选的催化基团,一个定位基团,允许共轭物在靶细胞或组织内积累,一个或多个有效载荷基团(例如,治疗剂或成像剂),以及与-杂原子核心共价结合的两个或更多个不干扰基团。
  • N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
    申请人:Rodgers James D.
    公开号:US20100298334A1
    公开(公告)日:2010-11-25
    The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
    本发明涉及式I的N-(杂)芳基吡咯烷衍生物: 这些是JAK抑制剂,如选择性JAK1抑制剂,在治疗JAK相关疾病方面具有用处,例如炎症和自身免疫性疾病,以及癌症。
  • OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY
    申请人:Masuda Koji
    公开号:US20120253040A1
    公开(公告)日:2012-10-04
    Disclosed is a compound which is useful as an endothelial lipase inhibitor. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is aromatic carbocycle or aromatic heterocycle, Z is —NR 5 —, —O— or —S—, R 5 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or the like, R 1 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like, R 2 and R 3 are each independently hydrogen, halogen, hydroxy or the like, R 4 is a group represented by the formula: —(CR 6 R 7 )n-R 8 , wherein R 6 and R 7 are each independently hydrogen, halogen, hydroxy or the like, n is an integer of 0 to 3, R 8 is carboxy, cyano, substituted or unsubstituted alkyl or the like, R x is halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like, m is an integer of 0 to 3.
    揭示了一种作为内皮酶抑制剂有用的化合物。 一种由下式表示的化合物: 其药学上可接受的盐,或其溶剂化合物, 其中 环A是芳香碳环或芳香杂环, Z是-NR 5 —,-O-或-S-, R 5 是氢,取代或未取代的烷基,取代或未取代的烯基,取代或未取代的炔基,取代或未取代的芳基或类似物, R 1 是氢,卤素,羟基,基,硝基,羧基,取代或未取代的烷基,取代或未取代的烯基或类似物, R 2 和R 3 各自独立地是氢,卤素,羟基或类似物, R 4 是由下式表示的基团:-(CR 6 R 7 )n-R 8 , 其中R 6 和R 7 各自独立地是氢,卤素,羟基或类似物,n是0到3的整数,R 8 是羧基,基,取代或未取代的烷基或类似物, R x 是卤素,羟基,基,硝基,羧基,取代或未取代的烷基,取代或未取代的烯基或类似物, m是0到3的整数。
  • Useful indole compounds
    申请人:Bartolini Wilmin
    公开号:US20070203209A1
    公开(公告)日:2007-08-30
    Indoles having various activities, including indoles that are CRTH2 are described. The compounds are useful for treating asthma, neuropathic pain, allegic rhinitis and other disorders.
    本文描述了具有多种活性的吲哚类化合物,包括CRTH2的吲哚类化合物。这些化合物可用于治疗哮喘、神经病性疼痛、过敏性鼻炎和其他疾病。
  • 7-HYDROXY-SPIROPIPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:US20150166538A1
    公开(公告)日:2015-06-18
    The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y 1 receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders.
    本发明提供了式(I)的化合物:如规范中定义的和包含任何此类新化合物的组合物。这些化合物是P2Y1受体的拮抗剂,可用作治疗和/或预防血栓栓塞性疾病的药物。
查看更多